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Abstract: 
Site-specific phenotypic effects of the 73 known alleles in the rhodopsin gene that cause retinal degeneration are 
difficult to interpret because most alleles are documented in only one case or one family, which means variation 
in effects could actually arise from interactions with other loci. However, sample sizes necessary to detect 
epistatk. interaction may place an answer to this question beyond our grasp. 
 
Article: 
[DAIGER ET AL.] The comprehensive review of DAIGER ET AL. documents genetic heterogeneity, allelic 
heterogeneity, and clinical heterogeneity in a diverse collection of mutations causing degeneration of the human 
retina. Listed here are 42 mapped loci, one of which (rhodopsin) has at least 73 alleles causing a wide array of 
phenotypes in terms of the quality, severity, and consistency of effects. While proposing a classification scheme 
to bring some order to a bewildering complexity in a single gene, the authors point out that many vital aspects 
of the gene's role in development remain unexplored. A great deal has been accomplished in the biochemical 
genetics of retinal degeneration, but continuing study suggests a limitless diversity and provokes questions 
about the goals of this research and the likelihood of achieving them. 
 
1. The chemically complete retina. Understanding a system of 42 genes is challenging enough, yet there must 
be thousands of genes expressed in the retina, many of which are fixed in the population and do not produce 
disease. It makes good sense to concentrate on genes associated with disorders of vision if one hopes to 
someday prevent blindness. At the same time, the connectedness of the metabolic system in the retina dictates 
that the effects of a mutation at one locus will not be well understood until its associated protein can be placed 
in a biochemical context that includes the protein products of fixed loci. Thus, it would be helpful to know how 
many genes are expressed in the retina and how many are unique to the retina. Is it important for science to 
identify and characterize all of these, and will this knowledge benefit those who suffer from retinal dystrophy? 
The target article has set forth much that is already known but, has given little more than a hint at the goals of 
this enterprise. In particular, will the knowledge of the DNA sequence of various alleles causing some form of 
retinal degeneration be used primarily to screen for genetic defects and possibly abort embryos destined to 
suffer reduced vision in later life, or is there hope for ameliorating these hereditary conditions when the specific 
allele is known? A simple catalog of alleles and phenotypes is sufficient for eugenic purposes, whereas practical 
intervention to prevent retinal degeneration will necessitate a much more comprehensive understanding of the 
relations between rhodopsin and its environment. 
 
2. Site-specific phenotypic effects? The answers to these questions will depend critically on the general 
properties of biochemical gene action. In particular, should we expect that changing a specific amino acid in a 
protein should result in a specific array of phenotypic effects at the level of retinal function in anyone 
possessing that allele? If yes, then there is no need to understand much about associated proteins derived from 
fixed loci or polymorphic loci not strongly tied to disease. The familiar catalog of loci related to specific disease 
syndromes can be expanded into a catalog of alleles or groupings of alleles, each with a characteristic 
syndrome. This seems to be the answer provided by the authors when they state ''the clinical phenotype is a 
consequence of where and when the mutation affects the function of rhodopsin" (sect. 4.2, para. 1). 
There is no doubt that an amino acid substitution in a critical protein can alter neural function. Rigorously 
controlled studies of oisogenic mice differing at a single amino acid in only one protein find that the mutants 
deviate phenotypically from their normal siblings, at least when group averages are compared. However, it does 
not follow that the average phenotypic difference is attributable solely to the amino acid difference. Coisogenic 
littermates share thousands of other genes and a multifaceted laboratory environment in common, and the ge-
netic difference occurs in a context that may be critically important for the phenotypic outcome. For example, 
epistatic interaction with the genetic background can markedly alter the consequences of mutations such as 
diabetes and reeler in mice (Cavincss et al. 1972; Coleman 1981) and interaction with the rearing environment 
can sometimes be quite dramatic (e.g., Lee & Bressler 1981). 
 
The appropriate research designs for assessing epistasis and gene-environment interaction always require 
individuals with a specific genotype at a designated locus to be combined with different genetic backgrounds or 
reared in different circumstances. To achieve this, the investigator must have access to a fairly large number of 
individuals carrying the identical mutation. In this regard, the yellow flag for caution begins to wave when the 
authors inform us in section 4.1.1 that "The majority of mutations in Table 2 are unique, occurring in one 
patient or one family only." Is it not possible or even likely that certain mutations with apparently variable 
effects are working in concert with other retinal genes that, while not causing disease on their own account, are 
interactants that strongly influence the consequences of a rare rhodopsin allele? And might not some of the 
apparently consistent effects of other mutations simply reflect the lack of genetic variation in interacting loci 
within certain families? The great phenotypic diversity attributed in this article to allelic heterogeneity may 
perhaps result from epistatic interaction or even gene-environment interaction, as DAIGER ET AL. 
acknowledge briefly in section 3.2.2. 
 
Of course, the argument can work both ways. When a mutation in a gene results in substantially different 
disease in different people, epistasis might be invoked to explain this, but the effect could just as well arise from 
allelic diversity. In this respect, reliable knowledge about the DNA sequence in the rhodopsin gene should help 
to discriminate between these two kinds of causes. We begin with the observations that there are in fact many 
alleles of the rhodopsin gene and there are also many phenotypes. But are the two variations closely associated 
and, if so, why? 
 
3. interaction, the night blindness of statistical analysis. It is instructive to explore the kinds of data that will 
be needed to address two important questions about allelic heterogeneity. Both of these involve the question of 
sample size required to render a statistical procedure sufficiently sensitive to more subtle genetic effects. 
 
One question is simply whether two alleles do indeed differ significantly in the frequency of associated 
phenotypes. Suppose most cases can be dichotomized into early and later onset of retinal degeneration, and let 
the probability of the early form be pi and p, for two alleles. The null hypothesis is that p1 = p2 = p, whereas the 
alternative hypothesis is that p1 = p + c and p2 = p — c, where c is the deviation from an average of the two 
alleles. If one plans to test the significance of a difference in sample proportions of the early onset form using a 
Z test with a Type I error probability of α, two-tailed, and wants the test to have Type II error probability β, 
equivalent to statistical power of 1 -β, then the appropriate sample size is given by a formula based on a normal 
approximation to the binomial distribution. 
 
Suppose p = .5. To achieve power of 90% when α = .05, the necessary sample sizes per group are indicated in 
Table 1. It could be quite difficult to find enough humans with each of the rare alleles. In this regard, it appears 
the authors are on the right track by seeking commonalities in terms of domain of action of various alleles, 
where samples could reasonably be pooled across similar alleles. 
 
In order to test the classification scheme more rigorously, it would help not only to work with adequate samples 
but also to obtain continuous measures of the phenotypes associated with retinal degeneration, such as age at 
onset of symptoms, rate of degeneration, and percent of the retina impaired. These dependent variables could 
then be assessed with multivariate statistics to determine the significance and strength of relationships with 
region occupied by a mutation (as in sects. 4.2.2 to 4.2.5). This would allow for exceptions, such as the 
1289de117 and 1312de124 mutations, to weaken an interesting relationship without negating it altogether. 
The other important question about phenotypic consequences of allelic heterogeneity concerns the possible role 
of epistasis. Two alleles might have quite different effects on one genetic background but appear to differ less 
radically on another background. Consider the example in Table 2 where hypothetical group means are given in 
arbitrary units. The allelic difference is twice as large on background B compared to A. A simple formula that 
provides a normal approximation to the noncentral t distribution is convenient for estimating the necessary 
sample sizes (Wahlsten 1991). Suppose the standard deviation within a group is σ = 7.5 units and a planned 
contrast is used to test the difference between the effects of the two alleles without regard to genetic 
background. To achieve power of 80% when a two-tailed test with α = .05 is used, the investigators must study 
about 10 patients in each of the four groups. However, to test the hypothesis of interaction between allele and 
genetic background with the same level of power, the sample size must be 73 patients per group! As a general 
rule, the necessary sample size is inversely proportional to the square of the size of the effect, Thus, the sample 
sizes appropriate for studying many kinds of interactions in a serious way are substantially larger than those that 
investigators commonly employ when looking at the average effects of an allelic difference [see Wahlsten 
"Insensitivity of the Analysis of Variance to Heredity-Environment Interaction" BBS 13(1) 1990]. 
 
        
 
The tyranny of numbers appears to render unanswerable the question of epistatic interaction when there are so 
few families with rare alleles. If we cannot address this question in a serious way, I believe investigators should 
inform readers that they cannot argue strongly for the reductionistic thesis that each allele or molecular domain 
codes for a specific clinical syndrome. 
 
Given the statistical difficulties of human genetic research, perhaps it might be helpful to assess allelic 
interactions in animal models of retinal degeneration using transgenic methods to create animals with different 
rare alleles. Once accomplished, large numbers of retinal degenerate mice could be produced. 
